GDX vs IBB
VanEck Gold Miners ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.51% for GDX.
- • GDX pays a higher dividend yield (0.84%).
Side-by-side metrics
| Metric | GDX | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.51% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.84% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $22.75B | $9.09B |
YTD return | -14.27% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.81 | 0.69 |
P/E ratio | 13.69 | 24.79 |
Last price | $76.00 | $196.62 |
Inception | — | — |
Issuer | VanEck | iShares |
GDX top holdings
| AEM.TO | Agnico Eagle Mines Ltd | 10.52% |
| NEM | Newmont Corp | 10.48% |
| ABX.TO | Barrick Mining Corp | 7.95% |
| WPM.TO | Wheaton Precious Metals Corp | 5.51% |
| AU | Anglogold Ashanti PLC | 5.07% |
| FNV.TO | Franco-Nevada Corp | 4.84% |
| K.TO | Kinross Gold Corp | 4.40% |
| GFI | Gold Fields Ltd ADR | 4.01% |
| PAAS.TO | Pan American Silver Corp | 2.95% |
| NST.AX | Northern Star Resources Ltd | 2.70% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About GDX
GDX (VanEck Gold Miners ETF) is Major gold mining companies. Managed by VanEck, the fund carries $22.8B in assets under management, an expense ratio of 0.51%, a dividend yield of 0.84%. Its largest holding is Agnico Eagle Mines Ltd (AEM.TO), which represents 10.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.